Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Portal Hypertension SIG: Critical Review of Invasive Interventions in Patients with Portal Hypertension

    Contains 9 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Join international portal hypertension experts for a critical review of several invasive interventions performed in patients with the disease. This session will look at potential situations that may interfere with the accuracy and reproducibility of hepatic venous pressure gradient and portal pressure gradient measurements in the course of TIPS. It will also discuss recommendations for standardizing the procedure. Attendees will hear a review of invasive procedures used to diagnose and treat cardiofundal and ectopic varices as well as new therapeutic strategies to solve portal hypertension in patients — both children and adults — with portal cavernoma. Finally, the session will review the potential role of splenectomy or spleen embolization in the treatment of hypersplenism and of the closing or reduction of TIPS or large portocollateral shunts in patients with severe refractory hepatic encephalopathy.

    Juan C. Garcia-Pagan

    Juan Carlos Garcia-Pagán is a Senior consultant in Hepatology and Head of the Hepatic Hemodynamic section at the Hospital Clinic in Barcelona, Spain and Associate Professor at the University of Barcelona.

    He is currently sharing its clinical activity in the hospital with its clinical and basic research at the Institut de Investigacións Biomediques August Pi i Sunyer (IDIBAPS) and is also member of the Centro para Investigación Biomédica en Red de enfermedades hepaticas y digestivas (CIBEREHD).  The main research of Interest are: Pathophysiology and treatment of portal hypertension in cirrhosis and of vascular disorders of the liver. He is currently the chair of the EASL-VALDIG (Vascular liver disease group) .

    Zachary Henry

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

    Frederik Nevens

    Riccardo A. Superina

    Riad Salem

    Wael E. Saad

    Dr. Saad is a Physician of 20 years and is internationally recognized for liver disease including liver transplantation, hepatobiliary disease and portal hypertension. He has over 240 publications and over 70 book chapters and is an author of 4 books. He completed his residency at the University of Rochester, New York and his Fellowship in Vascular & Interventional Radiology at Mallinckrodt Institute of radiology, Washington University, St. Louis. He practiced Interventional Radiology at the University of Rochester and University of Virginia, where he was the program director of the Vascular & Interventional Radiology Fellowship, before coming to the University of Michigan in 2013. Dr. Saad is active in the Society of Interventional Radiology (SIR) and was awarded the SIR-Fellowship in 2010. He served as the Chairman of the SIR Standards of Practice Committee from 2011 through to 2014.

  • Basic Research Workshop

    Product not yet rated Contains 9 Component(s) Recorded On: 11/13/2016

    AASLD's Basic Research Workshop presented at The Liver Meeting® 2016.

    This workshop will focus on how inducible pluripotent stem cells (iPSCs) can be used to produce liver cells and organoids. These are exciting new tools for experimental hepatology and hold great promise for clinical hepatology. The generation of iPSC-derived liver cells enables studies of the pathophysiology of several human conditions and to explore the effects of new drugs and treatment following a personalized medicine approach. iPSCs can also give rise to multicellular liver organoids with the potential to recapitulate the cellular ecosystem of a human liver, maintain the inter-cellular relationships, and reproduce models of liver disease as experimental models and potential organ-replacement strategies.

    Mario Strazzabosco

    Jorge A. Bezerra

    Stephen A. Duncan

    Takanori Takebe

    Holger Willenbring

    Romina Fiorotto

    Andrew A. Wilson

  • Clinical Hepatology Update 2017

    Contains 26 Component(s) Recorded On: 06/03/2017

    This course offers didactic lectures in 6 topic areas relevant to mid-level hepatology professionals.

    The 2017 Clinical Hepatology Course is a prime opportunity for hepatology professionals to stay updated on the state-of-the-art management of liver disease. Presentations will offer clinically relevant insights on many aspects in patient care in liver disease, and a chance to discuss controversies commonly seen in clinical practice with key leaders in the field.

    This 1 1/2 day course will offer didactic lectures in 6 topic areas relevant to mid-level hepatology professionals. A breakout session titled Preventative Health Strategies in the Outpatient Management of Cirrhosis will feature a small, interactive discussion with session organizers and networking opportunities with other attendees.

    K. Rajender Reddy

    Jayant A. Talwalker

    Frank Lammert

    Christopher L. Bowlus

    Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.

    Bernd Schnabl

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Michael B. Fallon

    Juan G. Abraldes

    Ram M. Subramanian

    Michael R. Lucey

    Kathleen E. Corey

    Natalie J. Torok

    R. Todd Stravitz

    Michael L. Schilsky

    Patrick S. Kamath

    Hashem B. El-Serag

    Saul J. Karpen

    Tram T. Tran

    Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Timothy J. Davern

  • Clinical Practice SIG: Managing and Growing a Hepatology Clinical Practice

    Product not yet rated Contains 10 Component(s) Recorded On: 11/11/2016

    AASLD's Clinical Practice SIG presented at The Liver Meeting® 2016.

    As the practice of hepatology has matured over the past decade many AASLD members have successfully developed or transitioned to community-based hepatology practices in one of three major areas: a community based health care system, a multi-speciality group practice or a hepatology-only medical practice. This workshop will bring together hepatologists, practice administrators, lawyers with medical practice speciality who work in these environments to share the medical, financial and legal models they utilize to develop successful, rewarding and financially feasible community-based hepatology practices.

    Marcelo Kugelmas

    David E. Bernstein

    Stephen A. Harrison

    Victor R. Araya

    Mitchell L. Shiffman

    Mitchell A. Mah'moud

    Tarek I. Hassanein

  • Career Development Workshop

    Product not yet rated Contains 7 Component(s) Recorded On: 11/11/2016

    AASLD's Career Development Workshop presented at The Liver Meeting® 2016.

    The main objective of this program is to educate medical students or residents who are considering a career in hepatology about training opportunities as well as arm the current GI and/or hepatology fellows with knowledge to help them succeed in academic hepatology. Time will be decidated specifically to discussion of clinical and basic science research, funding mechanisms, mentorship and important career crossroads. An overview of the responsibilities and opportunities of an academic hepatologist and clinician educator will all be provided. Community based, hybrid practices, and VA based hepatology opportunities/practice models will be discussed. Lastly, through panel discussion, the common questions regarding interview and contract negotiations will be reviewed by members of the panel. 

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Oren K. Fix

    William Sanchez

    Harmeet Malhi

    Archita P. Desai

    Mark W. Russo

  • Hepatology Associates Course

    Contains 12 Component(s) Recorded On: 10/22/2017

    AASLD's Hepatology Associates Course presented at The Liver Meeting® 2017.

    This comprehensive program has been designed to improve the treatment and management of patients with liver disease. By highlighting current data to support effective and efficient patient-centered care, attendees will have the ability to utilize medical knowledge and research to provide quality evidence-based practice. In addition, the program will address how quality improvement measures can be enhanced by working with interdisciplinary teams, and encourage attendees to evaluate their current practices by assimilating updated scientific evidence into patient focused care and management.

    Cynthia L. Solomon

    Daniel M. Tassone

    Nicolas M. Intagliata

    Rhonda K. Martin

    Maria L. Yataco

    Tram T. Tran

    Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Cristal L. Brown

    Amanda J. Chaney

    Michael Fuchs

    Cheryl Dale

  • 2017 Postgraduate Course: 21st Century Hepatology: Translating Discoveries into Practice

    Contains 21 Component(s) Recorded On: 10/21/2017

    AASLD's Postgraduate Course: 21st Century Hepatology presented at The Liver Meeting® 2017.

    Now, more than ever, hepatologists and hepatology health professionals must guide personalized treatment plans for their patients. 21st Century Hepatology will help you do just that by discussing new and best evidence, therapeutic advances, and breakthroughs on the horizon. From the application of biomarkers to genetics and lifestyle, this course offers a state-of-the art look at translating discoveries into modern-day hepatology practice.

    Ronald J. Sokol

    Michael P. Manns

    Marc G. Ghany

    Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    David R. Nelson

    Jasmohan S. Bajaj

    David E. Kleiner

    Rohit Loomba

    Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome.

    Quentin M. Anstee

    Gyongyi Szabo

    Hashem B. El-Serag

    Jorge A. Marrero

    Laura M. Kulik

    Francis Yao

    Cynthia Levy

    Jorge A. Bezerra

    Guruprasad P. Aithal

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Paolo Angeli

    R. Todd Stravitz

    Jacqueline G. O'Leary

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

  • Fundamentals of Liver Disease- Hepatitis C

    Contains 65 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:
    HCV: Epidemiology and Screening
    Patient with new diagnosis of HCV (anti-HCV positive)
    Assessing severity of liver disease in HCV
    Management of the Patient with Chronic HCV
    Management of the Chronic HCV Patient with co-morbid and other conditions
    Antiviral treatment of the patient with HCV infection
    Management of patients with HCV who have achieved a virological "cure"
    The Pediatric patient with HCV

    COMPONENTS
    Online:
    8 online interactive, narrated modules 30 to 40 minutes in length
    Pre- and post-test questions for each module

    Original release date: April 10, 2014
    Review date:July 1, 2017
    Re-release date: December 1, 2017
    Expiration date: November 30, 2019
    Time to complete each module: 45-60 minutes

    Copyright:
    All faculty in this activity have given their permission for publication OR
    ©2017 AASLD

    Contact Information
    For questions on CE credit for this activity contact Certificate@AmedcoEmail.com
    For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org.

    John W. Ward

    Nancy S. Reau

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Jordan J. Feld

    Sanjeev Arora

    Raymond T. Chung

    Michael W. Fried

    Andrew J. Muir

    Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

    Kathleen B. Schwarz

    Learning Objective:

    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    CME

    Accreditation Statement

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    AASLD designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse

    Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 4.0 contact hours.

    Maintenance of Certification (MOC) Statement

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    How to Earn/Claim MOC

     

    •    For each module that you wish to claim MOC points for you must:

     

                o    Complete the pre-test

     

                o    Review/watch the slides in the presentation

     

                o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

     

                o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

     

    •    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

     

    •    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
    The faculty, organizers and reviewers have reported the following disclosures:

    Juan Abraldes, MD
    Faculty
    Nothing to disclose

    Jasmahon Bajaj, MD
    Faculty
    Advisory Committees or Review Panels: ALF, ACG
    Consulting: Salix, Norgine and Alfa-Wasserman 
    Grant/Research Support: Grifols, Salix

    Thomas Boyer, MD
    Faculty
    Consulting: Ikaria
    Grant/Research Support: Ikaria

    Michael Fallon, MD
    Faculty
    Nothing to disclose

    Patrick Kamath, MD
    Faculty
    Advisory Committees or Review Panels: Sequana

    Paul Martin, MD
    Faculty
    Grant/Research Support: AbbVie and Genfit

    Puneeta Tandon, MD
    Faculty
    Nothing to disclose

    Florence Wong, MD
    Faculty
    Speakers' Bureau: L.W. Gore & Associates

    Sanjeev Arora, MD
    Organizer
    Advisory Committee: CDC Advisory Committee - Hep C
    Grant/Research Support: Gilead, Beckman Coulter, Merck, AbbVie

    Lauren Beste, MD
    Organizer
    Nothing to disclose

    Michael Fried, MD, FAASLD
    Organizer
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
    Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

    Guadalupe Garcia-Tsao, MD
    Organizer, Faculty
    Advisory Committee: Abbvie, Fibrogen

    Leslie Hayes, MD
    Organizer
    Nothing to disclose

    Patrick Horne, MSN, ARNP, FNP-BC
    Organizer
    Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

    Rennie Mills, PA-C
    Organizer
    Advisory Board: Gilead

    Minhhuyen Nguyen, MD
    Organizer
    Nothing to disclose

    Norah Terrault, MD
    Organizer
    Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
    Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
    Educational Material Development: CCO Hepatitis

    John Ward, MD
    Organizer
    Nothing to disclose

    Stephanie Graham, MA
    AASLD Staff
    Nothing to disclose

    Claudia Ventura
    AASLD Staff
    Nothing to disclose

    Online Learning Committee

    Calvin Q. Pan, MD, MACP, FAASLD
    Reviewer
    Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

    Lopa Mishra, MD, FAASLD
    Reviewer
    Nothing to Disclose

    Gene Y Im, MD
    Reviewer
    Nothing to Disclose

    Iris W Liou, MD
    Reviewer
    Nothing to Disclose

    Jesse M Civan, MD
    Reviewer
    Education: Merck

    HoChong Gilles, FNP
    Reviewer
    Nothing to Disclose

    Julius Wilder, MD, PhD
    Reviewer
    Nothing to Disclose

    Nicolas M Intagliata, MD
    Reviewer
    Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

    Andrew S. deLemos, MD
    Reviewer
    Consulting: Novartis

    Samar H. Ibrahim, MBCHB
    Reviewer
    Nothing to Disclose

    This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • Fundamentals of Liver Disease- Cirrhosis

    Contains 74 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:

    Does My Patient Have Cirrhosis?

    Natural History of Cirrhosis and General Management of the Compensated Patient

    Varices and Variceal Hemorrhage

    Ascites

    Hyponatremia and Hepatorenal Syndrome

    Hepatic Encephalopathy

    Infections in cirrhosis

    Pulmonary complications in the patient with cirrhosis

    Does my patient with cirrhosis need to be referred for liver transplant?

     

    COMPONENTS

    Online presentations comprised of PowerPoint slides and accompanying audio and online pre- and post-tests and evaluations:

    -9 online interactive, narrated modules 20 to 40 minutes in length

    -Pre- and post-test questions for each module

    Original release date: July 20, 2015
    Expiration date: July 19, 2017
    Review date: January 1 - November 30, 2017
    Re-release date: December 1, 2017
    Expiration date: November 30, 2019
    Time to complete each module: 45-60 minutes

     

    Copyright:

    All faculty in this activity have given their permission for publication OR

    ©2017 AASLD

     

    Contact Information

    For questions on CE credit for this activity, email Certificate@AmedcoEmail.com

    For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org

    Patrick S. Kamath

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Juan G. Abraldes

    Florence Wong

    Thomas D. Boyer

    Dr. Thomas D. Boyer is currently Professor of Medicine and Director of the Liver Research Institute at the University of Arizona School of Medicine in Tucson, Arizona. He has a longstanding interest in the complications of portal hypertension including bleeding varices, ascites, and hepatorenal syndrome. Dr. Boyer has published a number of papers in each of these areas of interest.

    Jasmohan S. Bajaj

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

    Michael B. Fallon

    Paul Martin

    Learning Objective:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    CME

    Accreditation Statement

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    AASLD designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse

    Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 4.5 contact hours.

    MOC

    Maintenance of Certification (MOC) Statement 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    How to Earn/Claim MOC

     

    •    For each module that you wish to claim MOC points for you must:

     

                o    Complete the pre-test

     

                o    Review/watch the slides in the presentation

     

                o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

     

                o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

     

    •    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

     

    •    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
    The faculty, organizers and reviewers have reported the following disclosures:

    Juan Abraldes, MD
    Faculty
    Nothing to disclose

    Jasmahon Bajaj, MD
    Faculty
    Advisory Committees or Review Panels: ALF, ACG
    Consulting: Salix, Norgine and Alfa-Wasserman 
    Grant/Research Support: Grifols, Salix

    Thomas Boyer, MD
    Faculty
    Consulting: Ikaria
    Grant/Research Support: Ikaria

    Michael Fallon, MD
    Faculty
    Nothing to disclose

    Patrick Kamath, MD
    Faculty
    Advisory Committees or Review Panels: Sequana

    Paul Martin, MD
    Faculty
    Grant/Research Support: AbbVie and Genfit

    Puneeta Tandon, MD
    Faculty
    Nothing to disclose

    Florence Wong, MD
    Faculty
    Speakers' Bureau: L.W. Gore & Associates

    Sanjeev Arora, MD
    Organizer
    Advisory Committee: CDC Advisory Committee - Hep C
    Grant/Research Support: Gilead, Beckman Coulter, Merck, AbbVie

    Lauren Beste, MD
    Organizer
    Nothing to disclose

    Michael Fried, MD, FAASLD
    Organizer
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
    Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

    Guadalupe Garcia-Tsao, MD
    Organizer, Faculty
    Advisory Committee: Abbvie, Fibrogen

    Leslie Hayes, MD
    Organizer
    Nothing to disclose

    Patrick Horne, MSN, ARNP, FNP-BC
    Organizer
    Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

    Rennie Mills, PA-C
    Organizer
    Advisory Board: Gilead

    Minhhuyen Nguyen, MD
    Organizer
    Nothing to disclose

    Norah Terrault, MD
    Organizer
    Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
    Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
    Educational Material Development: CCO Hepatitis

    John Ward, MD
    Organizer
    Nothing to disclose

    Stephanie Graham, MA
    AASLD Staff
    Nothing to disclose

    Claudia Ventura
    AASLD Staff
    Nothing to disclose

    Online Learning Committee

    Calvin Q. Pan, MD, MACP, FAASLD
    Reviewer
    Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

    Lopa Mishra, MD, FAASLD
    Reviewer
    Nothing to Disclose

    Gene Y Im, MD
    Reviewer
    Nothing to Disclose

    Iris W Liou, MD
    Reviewer
    Nothing to Disclose

    Jesse M Civan, MD
    Reviewer
    Education: Merck

    HoChong Gilles, FNP
    Reviewer
    Nothing to Disclose

    Julius Wilder, MD, PhD
    Reviewer
    Nothing to Disclose

    Nicolas M Intagliata, MD
    Reviewer
    Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

    Andrew S. deLemos, MD
    Reviewer
    Consulting: Novartis

    Samar H. Ibrahim, MBCHB
    Reviewer
    Nothing to Disclose

    This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • Clinical Hepatology Update 2018

    Contains 17 Component(s), Includes Credits

    The goal of the 2018 Clinical Hepatology Update is to allow medical professionals the opportunity to review the up-to-date diagnosis and management of a variety of liver diseases with experts and leaders in the field of Hepatology. This course will also cover ongoing research in a variety of liver related topics which will potentially have significant impact on the future practice of Clinical Hepatology. The content features academic leaders in Hepatology who are actively contributing to these advances.

    The goal of the 2018 Clinical Hepatology Update is to allow medical professionals the opportunity to review the up-to-date diagnosis and management of a variety of liver diseases with experts and leaders in the field of Hepatology. This course will also cover ongoing research in a variety of liver related topics which will potentially have significant impact on the future practice of Clinical Hepatology. The content features academic leaders in Hepatology who are actively contributing to these advances.


    Core Competencies:  

    • Patient-centered Care
    • Work in Interdisciplinary Teams
    • Evidence-based Practice
    • Quality Improvement
    • Patient Care
    • Medical Knowledge
    • Practice Based Learning and Improvement 
    • Cognitive Expertise  

    Program Chairs

    • Hari S. Conjeevaram, MD, MS
    • Coleman I. Smith, MD, FAASLD
    • Elizabeth K. Goacher, PA-C, MHS
    • April G. Morris, FNP

    Components

    Learners will: 

    • Listen to 6 self-directed recorded sessions (90 - 135 minutes in length) while following along with visual slides
    • Take a post-activity quiz for each session
    • Answer evaluation questions

    All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Release Date: September 20, 2018
    Expiration Date: September 19, 2020


    Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD

    Hari Conjeevaram (Moderator)

    Coleman I. Smith (Moderator)

    Elizabeth K. Goacher (Moderator)

    Zobair M. Younossi

    Robert J. Fontana

    Victor J. Navarro

    Lindsay King

    Amol S. Rangnekar

    Jessica L. Mellinger

    Stephen H. Caldwell

    Dr. Stephen Caldwell is a hepatologist specializing in a nonalcoholic steatohepatitis (NASH), including its relationship to so-called cryptogenic cirrhosis, ethnic and familial relationships and the role of mitochondrial dysfunction in the disease. He and his colleagues pioneered work on cellular ballooning and the role of small fat droplets in NASH and have also worked extensively with cyanoacrylates in the treatment of gastric variceal bleeding. He is overseeing a number of treatment trials for NASH and related liver fibrosis and is closely involved with a network of physicians and scientists working with coagulation disorders in liver disease. In 1992, he joined the faculty at UVA, helping to develop the hepatology program. Now a professor of medicine in the Division of Gastroenterology and Hepatology at UVA, Dr. Caldwell is board-certified in internal medicine and gastroenterology.

    Elliot B. Tapper

    Dr. Elliot Tapper is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

    Matthew R. Kappus

    April G. Morris

    Cynthia Moylan

    Mishal Mendiratta-Lala

    Christine Hsu

    Catherine Frenette

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Michael B. Fallon

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

    Mitchell L. Shiffman

    Nancy S. Reau

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Upon completion of this activity, learners will be able to: 

    • Discuss the management of patients with a variety of common problems in liver disease.
    • Become familiar with ongoing advances in hepatology and their potential application to clinical practice.
    • Implement evidence-based treatment in a variety of liver diseases

    • Hepatologists 
    • Gastroenterologists    
    • Nurse Practitioners
    • Physician Assistants  
    • Pharmacists               
    • Transplant Coordinators
    • Surgeons        
    • Fellows/Trainees        
    • Other physicians Specify: Primary care MDs
    • Other healthcare professionals Specify: Clinical researchers in the field of liver disease

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    CME 

    Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation AASLD designates this enduring activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Maintenance of Certification

    American Board of Internal Medicine (ABIM) MOC Statement 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Pediatrics (ABP) MOC Statement

    “Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 12.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”

    MOC Points Process

    Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.

    CE Credit

    image

    Nurses

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 12.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.  


    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Hari S. Conjeevaram, MD, MS
    Faculty
    Nothing to disclose

    Elizabeth K. Goacher, PA-C, MHS
    Faculty
    Advisory Boards and/or Review Panels: AbbVie Pharmaceuticals, Gilead Pharmaceuticals
    Speakers' Bureau: AbbVie Pharmaceuticals; Gilead Pharmaceuticals

    Robert J. Fontana, MD, FAASLD
    Faculty
    Consulting: Alynam Pharmaceuticals
    Grants/Research Support: BMS, Gilead, Abbvie

    Victor J. Navarro , MD, FAASLD
    Faculty
    Nothing to disclose

    Lindsay Y. King, MD 
    Faculty
    Nothing to disclose

    Amol S. Rangnekar, MD
    Faculty
    Nothing to disclose

    Michael B. Fallon, MD, FAASLD
    Faculty
    Nothing to disclose

    Stephen H. Caldwell, MD, FAASLD
    Faculty
    Advisory Committees or Review Panels: Gencia
    Grants/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed
    Royalties: Halyard

    Elliott B. Tapper, MD
    Faculty
    Grants/Research Support: Valeant, Gilead 

    Matthew R. Kappus, MD 
    Faculty
    Nothing to disclose

    Jessica Mellinger, MD
    Faculty
    Grants/Research Support: Salix Pharmaceuticals

    April G. Morris , FNP
    Faculty
    Advisory Boards and/or Review Panels: AbbVie, Inc., Merck & Co.
    Speakers' Bureau: Gilead, AbbVie, Inc.

    Zobair M. Younossi , MD, MPH, FAASLD
    Faculty
    Advisory Boards and/or Review Panels: Gilead, BMS, Intercept, Abbvie and GSK
    Consulting: Gilead, Intercept

    Cynthia A. Moylan, MD
    Faculty
    Grants/Research Support: TaiwanJ Pharmeceuticals, Madrigal Pharmaceuticals, Conatus

    Mishal Mendiratta-Lala, MD
    Faculty
    Nothing to disclose

    Christine Hsu, MD
    Faculty
    Nothing to disclose

    Catherine T. Frenette, MD
    Faculty
    Advisory Boards and/or Review Panels: Bayer, Intercept
    Speakers' Bureau: Bayer, Gilead 

    Puneeta Tandon, MD, FRCP
    Faculty
    Nothing to disclose

    Mitchell L. Shiffman, MD, FAASLD
    Faculty
    Advisory Boards and/or Review Panels: Abbvie, BMS, Gilead, Intercept, Merck, Salix
    Grants/Research Support: Abbvie, BMS, Conatus, CymaBay, Exalenz, Galectin, Genfit, Intercept, Immuron, Merck, NGMBio, Novartis, Shire
    Speakers' Bureau: Abbvie, Bayer, BMS, Daiichi Sankyo, Gilead, Intercept, Merck

    Nancy Reau, MD, FAASLD
    Faculty
    Advisory Boards and/or Review Panels: AbbVie
    Consulting: Gilead, Abbott, Merck 

    Coleman I. Smith, MD, FAASLD
    Faculty
    Adisory Board and/or Review Panels: BMS, Dova
    Grants/Research Support: Promethius, Genfit, Intercept, Conatus, Gilead, Abbvie, BMS
    Speakers' Bureau: Gilead, Abbvie

    Norah Terrault, MD, PhD
    Faculty
    Advisory Committees or Review Panels: Merck, Intercept, Conatus; Consulting: CCO Hepatitis, Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc.
    Grants/Research Support: AbbVie, Biotest, Eisai, Gilead, BMS, Merck, Allergan
    Royalties: UpToDate

    Anne Wrobel
    Staff Liason
    Nothing to disclose

    Sheryl Morgan, CE Coordinator
    Amedco Staff
    Nothing to disclos

    Acknowledgement of Financial or In-Kind Commercial Support

    No financial or in-kind commercial support was received for this educational activity.